Cassava Sciences has announced that its experimental drug for Alzheimer’s disease, simufilam, did not meet either its primary or secondary objectives in a crucial late-stage study. The company confirmed on Monday that the treatment showed no significant reduction in cognitive or functional decline compared to a placebo in patients with mild-to-moderate Alzheimer’s disease.
Following the disappointing results, Cassava stated it would halt a second late-stage trial of simufilam, as well as its open-label study. The news caused the company’s stock to plummet nearly 5% in premarket trading.
